Catalyst Pharmaceuticals, Inc. announces a Settlement Agreement with Lupin Ltd and Lupin Pharmaceuticals, Inc., resolving patent litigation over the generic version of FIRDAPSE®. Lupin will not market the generic version in the U.S. before February 25, 2035, pending FDA approval. Litigation with Teva Pharmaceuticals and Inventia Healthcare Limited was settled previously, while litigation with Hetero is ongoing. The confidential settlement agreement will be submitted to the Federal Trade Commission and the Department of Justice for review. Catalyst Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of patients with rare diseases.

Read more at GlobeNewswire: UPDATED- Catalyst Pharmaceuticals Announces Settlement of